X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (50807) 50807
Newsletter (5185) 5185
Book Chapter (82) 82
Dissertation (62) 62
Newspaper Article (55) 55
Conference Proceeding (27) 27
Magazine Article (25) 25
Publication (17) 17
Book / eBook (15) 15
Book Review (2) 2
Government Document (2) 2
Journal / eJournal (1) 1
Paper (1) 1
Reference (1) 1
Streaming Video (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
animals (24508) 24508
humans (20391) 20391
oligopeptides - pharmacology (17754) 17754
oligopeptides - chemistry (13402) 13402
oligopeptides (11676) 11676
amino acid sequence (11153) 11153
male (10664) 10664
biochemistry & molecular biology (10099) 10099
oligopeptides - metabolism (9591) 9591
mice (8316) 8316
molecular sequence data (8213) 8213
rats (8197) 8197
peptides (6812) 6812
female (6572) 6572
research (6074) 6074
oligopeptides - chemical synthesis (5170) 5170
kinetics (4797) 4797
pharmacology & pharmacy (4501) 4501
proteins (3660) 3660
analysis (3501) 3501
structure-activity relationship (3413) 3413
protein conformation (3292) 3292
models, molecular (3273) 3273
cells, cultured (3225) 3225
oligopeptides - therapeutic use (3217) 3217
expression (3027) 3027
protein binding (2857) 2857
dose-response relationship, drug (2835) 2835
oligopeptides - administration & dosage (2830) 2830
binding sites (2825) 2825
cell biology (2747) 2747
cell line (2700) 2700
in vitro techniques (2574) 2574
chemistry, multidisciplinary (2486) 2486
cell line, tumor (2425) 2425
substrate specificity (2410) 2410
biophysics (2281) 2281
adult (2268) 2268
ligands (2206) 2206
middle aged (2189) 2189
time factors (2185) 2185
apoptosis (2107) 2107
oligopeptides - immunology (2093) 2093
binding (2077) 2077
oligopeptides - genetics (2062) 2062
rats, sprague-dawley (2040) 2040
immunology (2019) 2019
protein (2004) 2004
peptide (2002) 2002
cells (1942) 1942
identification (1863) 1863
chemistry, medicinal (1806) 1806
neurosciences (1790) 1790
molecular structure (1780) 1780
oncology (1766) 1766
physiological aspects (1765) 1765
research article (1733) 1733
peptides - chemistry (1718) 1718
activation (1701) 1701
cancer (1633) 1633
amino acids (1608) 1608
chemistry, organic (1572) 1572
rats, wistar (1549) 1549
microbiology (1542) 1542
hydrogen-ion concentration (1539) 1539
in-vitro (1515) 1515
receptor (1515) 1515
endocrinology & metabolism (1464) 1464
apoptosis - drug effects (1453) 1453
protein structure, secondary (1447) 1447
cattle (1440) 1440
oligopeptides - pharmacokinetics (1397) 1397
magnetic resonance spectroscopy (1396) 1396
phosphorylation (1388) 1388
base sequence (1385) 1385
aged (1383) 1383
mice, inbred c57bl (1380) 1380
enzymes (1362) 1362
chromatography, high pressure liquid (1361) 1361
biochemical research methods (1349) 1349
multidisciplinary sciences (1342) 1342
rabbits (1334) 1334
tumor cells, cultured (1316) 1316
hydrolysis (1311) 1311
biotechnology & applied microbiology (1282) 1282
gene expression (1274) 1274
cell adhesion (1267) 1267
medicine, research & experimental (1259) 1259
chemistry (1246) 1246
inhibition (1231) 1231
disease models, animal (1229) 1229
signal transduction (1222) 1222
universities and colleges (1222) 1222
oligopeptides - analysis (1212) 1212
chemistry, analytical (1180) 1180
molecular weight (1176) 1176
mice, inbred balb c (1161) 1161
chemistry, physical (1160) 1160
in-vivo (1150) 1150
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (54594) 54594
Russian (868) 868
Japanese (710) 710
Chinese (292) 292
German (256) 256
French (127) 127
Spanish (73) 73
Italian (23) 23
Polish (18) 18
Czech (14) 14
Hungarian (14) 14
Korean (12) 12
Portuguese (12) 12
Ukrainian (12) 12
Danish (6) 6
Slovak (5) 5
Dutch (4) 4
Finnish (4) 4
Swedish (3) 3
Bulgarian (2) 2
Croatian (2) 2
Hebrew (2) 2
Greek (1) 1
Norwegian (1) 1
Romanian (1) 1
Serbian (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Hepatology, ISSN 0168-8278, 2010, Volume 54, Issue 6, pp. 1114 - 1122
Background & Aims BI201335 is a highly specific and potent HCV protease inhibitor. This multiple rising dose trial evaluated antiviral activity and safety in... 
Gastroenterology and Hepatology | Antiviral | Resistant variants | Hepatitis C virus | Pegylated interferon | Ribavirin | PLUS RIBAVIRIN | BILN-2061 | TELAPREVIR | EFFICACY | VX-950 | HEPATITIS-C-VIRUS | IN-VITRO | EARLY ANTIVIRAL ACTIVITY | PEGINTERFERON ALPHA-2A | ATAZANAVIR | GASTROENTEROLOGY & HEPATOLOGY | Antiviral Agents - pharmacokinetics | Hepatitis C - drug therapy | Protease Inhibitors - pharmacokinetics | Humans | Middle Aged | Hepacivirus - genetics | Male | Thiazoles - administration & dosage | Recombinant Proteins | Oligopeptides - adverse effects | Thiazoles - adverse effects | Thiazoles - pharmacokinetics | Protease Inhibitors - pharmacology | Hepatitis C - blood | Ribavirin - administration & dosage | Protease Inhibitors - administration & dosage | Protease Inhibitors - adverse effects | Adult | Female | Hepacivirus - drug effects | Antiviral Agents - pharmacology | Double-Blind Method | Oligopeptides - pharmacokinetics | Carrier Proteins - antagonists & inhibitors | Viral Nonstructural Proteins - genetics | Antiviral Agents - administration & dosage | Polyethylene Glycols - administration & dosage | Interferon-alpha - administration & dosage | Drug Resistance, Viral - genetics | Hepacivirus - enzymology | Antiviral Agents - adverse effects | Hepatitis C - virology | Oligopeptides - administration & dosage | Thiazoles - pharmacology | Oligopeptides - pharmacology | Viral Load - drug effects | Viral Nonstructural Proteins - antagonists & inhibitors | Medical colleges | Antiviral agents | Care and treatment | Safety and security measures | Hotels and motels | Immunodeficiency | Aspartate | Biological response modifiers | HIV (Viruses) | Anti-HIV agents | Complications and side effects | Protease inhibitors | Proteases | Genetic aspects | Hepatitis C | Viral Nonstructural Proteins | Oligopeptides | Polyethylene Glycols | Interferon-alpha | Protease Inhibitors | Drug Resistance, Viral | Antiviral Agents | Viral Load | Life Sciences | Thiazoles | Hepacivirus | Carrier Proteins | Cancer
Journal Article
Science (American Association for the Advancement of Science), ISSN 1095-9203, 2010, Volume 328, Issue 5981, pp. 1031 - 1035
Poor penetration of anticancer drugs into tumors can be an important factor limiting their effícacy. We studied mouse tumor models to show that a previously... 
Molecules | Intravenous injections | Medical treatment | REPORTS | Antineoplastics | Antibodies | Liposomes | Dosage | Prostate cancer | Tumors | Cancer | NANOPARTICLES | INTEGRINS | MULTIDISCIPLINARY SCIENCES | MOUSE MODEL | IN-VIVO | DOXORUBICIN | PHAGE DISPLAY | VASCULAR-PERMEABILITY FACTOR | CELL | ENDOTHELIAL GROWTH-FACTOR | DELIVERY | Neoplasms - metabolism | Doxorubicin - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Neuropilin-1 - metabolism | Albumin-Bound Paclitaxel | Humans | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Capillary Permeability - drug effects | Antibodies, Monoclonal - therapeutic use | Antineoplastic Agents - therapeutic use | Paclitaxel - pharmacokinetics | Antineoplastic Agents - administration & dosage | Albumins - therapeutic use | Antibodies, Monoclonal, Humanized | Antineoplastic Agents - pharmacokinetics | Paclitaxel - administration & dosage | Doxorubicin - administration & dosage | Oligopeptides - pharmacokinetics | Antibodies, Monoclonal - pharmacokinetics | Albumins - administration & dosage | Neoplasms - blood supply | Oligopeptides - metabolism | Permeability | Paclitaxel - therapeutic use | Doxorubicin - pharmacokinetics | Neoplasms - drug therapy | Xenograft Model Antitumor Assays | Albumins - pharmacokinetics | Animals | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Mice | Oligopeptides - administration & dosage | Oligopeptides - pharmacology | Trastuzumab | Antimitotic agents | Peptides | Research | Antineoplastic agents | Drug therapy | Health aspects | Chemotherapy | Drugs | Nanoparticles | Side effects | Doxorubicin | Constraining
Journal Article
The lancet oncology, ISSN 1470-2045, 2016, Volume 17, Issue 1, pp. 27 - 38
Journal Article
Journal of the American Chemical Society, ISSN 0002-7863, 12/2014, Volume 136, Issue 48, pp. 16940 - 16946
Although the syntheses of novel and diverse peptides rely mainly on traditional coupling using unnatural amino acids, postsynthetic modification of peptides... 
Amino Acids - chemistry | Oligopeptides - chemical synthesis | Ligands | Oligopeptides - chemistry | Molecular Conformation
Journal Article
The Journal of nuclear medicine (1978), ISSN 0161-5505, 2014, Volume 55, Issue 8, pp. 1248 - 1252
Journal Article
European journal of organic chemistry, ISSN 1434-193X, 06/2016, Volume 2016, Issue 16, p. 2815
Journal Article
PLoS ONE, ISSN 1932-6203, 2009, Volume 4, Issue 12, pp. e8334 - e8334
Background: Kisspeptin and its G protein-coupled receptor (GPR) 54 are essential for activation of the hypothalamo-pituitary-gonadal axis. In the rat, the... 
MONKEY MACACA-MULATTA | GONADOTROPIN-RELEASING-HORMONE | RHESUS-MONKEY | BIOLOGY | PITUITARY-GONADAL AXIS | MEDIAN-EMINENCE | PULSATILE LH-RELEASE | ELECTRICAL-ACTIVITY | HYPOGONADOTROPIC HYPOGONADISM | OVARIECTOMIZED RATS | LUTEINIZING-HORMONE | Oligopeptides - antagonists & inhibitors | Preoptic Area - drug effects | Arcuate Nucleus of Hypothalamus - metabolism | Injections, Intraventricular | Rats | Luteinizing Hormone - metabolism | Oligopeptides - metabolism | Preoptic Area - metabolism | Rats, Sprague-Dawley | Kisspeptins | Animals | Signal Transduction - drug effects | Arcuate Nucleus of Hypothalamus - drug effects | Gonadotropin-Releasing Hormone - metabolism | Female | Oligopeptides - administration & dosage | Oligopeptides - pharmacology | Brain | Medical examination | Luteinizing hormone | Glycoproteins | Hormones, Sex | G proteins | Hormones | Blood | Membrane proteins | Neurosciences | Intravenous administration | Arcuate nucleus | 17β-Estradiol | Hypothalamus | Nuclei | Rodents | Pituitary-gonadal axis | Cannulae | Puberty | Medical research | Preoptic area | Ovariectomy | Secretion | Neurons | Pulse generators | Pituitary (anterior) | Gonadotropins | Monkeys & apes | Catheters | Sex hormones | Signaling | Brain research | Pituitary | Infertility | Gonadotropin-releasing hormone | Kiss1 protein | Endocrinology
Journal Article
European Journal of Cancer, ISSN 0959-8049, 2012, Volume 48, Issue 18, pp. 3319 - 3327
Abstract Background SF1126 is a peptidic pro-drug inhibitor of pan-PI3K/mTORC. A first-in-human study evaluated safety, dose limiting toxicities (DLT), maximum... 
Hematology, Oncology and Palliative Medicine | Pharmacodynamics | PI3K/mTORC pathway | SF1126 | Pharmacokinetics | Refractory solid tumours | B-cell malignancies | ACTIVATION | ANGIOGENESIS | PHOSPHATIDYLINOSITOL 3-KINASE | KINASE | GUIDELINES | CANCER | ONCOLOGY | PI3K PATHWAY | CHRONIC LYMPHOCYTIC-LEUKEMIA | INHIBITOR | ASSOCIATION | Humans | Middle Aged | Male | Neoplasm Proteins - antagonists & inhibitors | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Phosphatidylinositol 3-Kinases - antagonists & inhibitors | Oligopeptides - therapeutic use | Young Adult | Chromones - adverse effects | Aged, 80 and over | Antineoplastic Agents - pharmacokinetics | Chromones - pharmacology | Protein Kinase Inhibitors - pharmacokinetics | Lymphoma, Large B-Cell, Diffuse - drug therapy | Lymphoma, Large B-Cell, Diffuse - enzymology | Neoplasms - drug therapy | Protein Kinase Inhibitors - administration & dosage | Leukemia, Lymphocytic, Chronic, B-Cell - enzymology | Maximum Tolerated Dose | Oligopeptides - administration & dosage | TOR Serine-Threonine Kinases | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Oligopeptides - pharmacology | Proteins - antagonists & inhibitors | Prodrugs - administration & dosage | Multiprotein Complexes | Salvage Therapy | Chromones - administration & dosage | Molecular Targeted Therapy | Oligopeptides - adverse effects | Mechanistic Target of Rapamycin Complex 1 | Dose-Response Relationship, Drug | Antineoplastic Agents - adverse effects | Hypokalemia - chemically induced | Adult | Female | Antineoplastic Agents - pharmacology | Chromones - therapeutic use | Hematologic Diseases - chemically induced | Oligopeptides - pharmacokinetics | Neoplasms - enzymology | Chromones - pharmacokinetics | Prodrugs - adverse effects | Prodrugs - pharmacokinetics | Protein Kinase Inhibitors - therapeutic use | Aged | Prodrugs - therapeutic use | Protein Kinase Inhibitors - pharmacology | Infusions, Intravenous | Prodrugs - pharmacology | Gastrointestinal Diseases - chemically induced | Medicine, Experimental | Medical research | Care and treatment | Emergency medical services | Cancer | Index Medicus | PI3K | mTORC pathway
Journal Article
Journal Article
Immunology, ISSN 0019-2805, 2018, Volume 154, Issue 3, pp. 394 - 406
Journal Article